Mallinckrodt shares slide 4% premarket after pain treatment approval delayed - MarketWatch https://t.co/5ZDo1wyyvt — IDRO (@IDROOhio) December 12, 2018
Mallinckrodt shares slide 4% premarket after pain treatment approval delayed - MarketWatch https://t.co/5ZDo1wyyvt
No comments:
Post a Comment